The Omega-6/Omega-3 Ratio as a Mortality Biomarker: Bridging Observational Data and Interventional Null Results

Selected angle: source

One-sentence thesis

The direct receipts support a narrow working claim: Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty NNT of 272; but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

Real tension: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

Evidence receipts

• fact_id=140174 (A_core) — Supplementation was associated with reduced risk of MI (relative risk [RR], 0.87; 95% CI, 0.80 to 0.96), high certainty NNT of 272 doi=10.1016/j.mayocp.2020.08.034
• fact_id=140175 (A_core) — but not CVD events (RR, 0.95; 95% CI, 0.90 to 1.00) doi=10.1016/j.mayocp.2020.08.034
• fact_id=140176 (A_core) — CHD events (RR, 0.90; 95% CI, 0.84 to 0.97), high certainty NNT of 192 doi=10.1016/j.mayocp.2020.08.034
• fact_id=138000 (A_core) — Participants who received omega-3 were 700 (65.06%) compared to 376 (34.94%) who received a placebo. doi=10.7759/cureus.30091
• fact_id=185966 (A_core) — Comparing the highest to the lowest quintiles, individuals had 31% (95% CI, 10–55%) higher CVD mortality doi=10.7554/elife.90132.3
• fact_id=185965 (A_core) — Comparing the highest to the lowest quintiles, individuals had 14% (95% CI, 0–31%) higher cancer mortality doi=10.7554/elife.90132.3
• fact_id=185964 (A_core) — Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15–38%) higher total mortality doi=10.7554/elife.90132.3
• fact_id=1138 (A_core) — little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% CI 0.93 to 1.01 doi=10.1002/14651858.cd003177.pub5
• fact_id=178493 (A_core) — the 3 treatments combined showed a significant 39% decreased odds of becoming prefrail compared to the control doi=10.1093/gerona/glad073

Context receipts

Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim.

• fact_id=143791 (B_context) — doses of 4 g/day (instead of the more common <1 g/day) doi=10.1007/s11936-016-0487-1
• fact_id=94952 (B_context) — omega-3 fatty acid supplements at more than 2 g/day may contribute to muscle mass gain (0.67 kg; 95% CI: 0.16, 1.18) doi=10.3390/nu12123739

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=1138 (A_core) — little or no effect of increasing LCn3 on all-cause mortality (risk ratio (RR) 0.97, 95% CI 0.93 to 1.01 Source: Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

Next extraction

• Extract independent A_core/B_context receipts that test the lead contrast directly.
• Audit whether each direct receipt remains comparable on population, endpoint, comparator, and measurement method.
• Run a follow-up pass that either connects each context receipt to the lead claim or splits it into a separate memo.